What is Viking Therapeutics's net investment in lease?

Viking Therapeutics (VKTX) reported net investment in lease of $0 in Q1 2026.

How has Viking Therapeutics's net investment in lease changed year-over-year?

Viking Therapeutics's net investment in lease decreased by 100.0% year-over-year, from $892K to $0.

What is the long-term trend for Viking Therapeutics's net investment in lease?

Over 5 years (2020 to 2025), Viking Therapeutics's net investment in lease has grown at a -23.3% compound annual growth rate (CAGR), from $321K to $85K.

Viking Therapeutics VKTX Net Investment in Lease

Net Investment in Lease at other companies

Madrigal Pharmaceuticals, Inc.MDGL

——

MBX Biosciences, Inc.MBX

——

Viridian Therapeutics, Inc.VRDN

——

Crinetics PharmaceuticalsCRNX

——

Amylyx Pharmaceuticals, Inc.AMLX

——

Rhythm Pharmaceuticals, Inc.RYTM

——

Other financials

Income statement

See full

Revenue-—

Operating income-$164.1M-196%

Net income-$158.3M-247%

EPS (diluted)-$1.37-234%

Balance sheet

See full

Cash & equivalents$118.1M+211%

Total debt$137.0K-87.8%

Total equity$501.9M-40.7%

Total assets$608.2M-29.8%

Cash flow

See full

Operating cash flow-$114.0M-118%

Valuation

See full

Market cap$4.04B+38.7%

Returns & leverage

See full

Return on equity-70%-94.5pp

Debt / equity0×0.0×

Current ratio5.7×-38.5×

Where this comes from

Reported directly by Viking Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.

The official record: Viking Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Viking Therapeutics's net investment in lease.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Viking Therapeutics's net investment in lease?: Viking Therapeutics (VKTX) reported net investment in lease of $0 in Q1 2026.
How has Viking Therapeutics's net investment in lease changed year-over-year?: Viking Therapeutics's net investment in lease decreased by 100.0% year-over-year, from $892K to $0.
What is the long-term trend for Viking Therapeutics's net investment in lease?: Over 5 years (2020 to 2025), Viking Therapeutics's net investment in lease has grown at a -23.3% compound annual growth rate (CAGR), from $321K to $85K.